A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00554346

Enrollment

Registered

2007-11-06

Start date

2008-05-31

Completion date

2010-06-30

Last updated

2010-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operational Pain

Keywords

COX-2; post-operative ; sports injury; surgical pain

Brief summary

Post surgical pain associated with ligament reconstruction may persist for few days after the surgical procedure. Arcoxia is a new anti-inflammatory and analgesic drug that alleviate pain through oral administration. This study will test the safety and efficacy of Arcoxia in the management of post-operational pain in patients receive the ligament reconstruction surgery.

Interventions

DRUGArcoxia(etoricoxib 90 mg/tablet)

Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

16 Years to 35 Years

Healthy volunteers

Inclusion criteria

1. Men and women age ranged from 16\ 35 who have anterior cruciate ligament injury and/or associated injuries are scheduled for ACL reconstruction surgery. 2. Patient agrees to participate into this study and is willing to sign the patient informed consent form.

Design outcomes

Primary

Measure	Time frame
Pain at rest at different timepoint after surgical procedures	From baseline(preoperation) to 3 days after

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026